S126: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. RESULTS FROM THE NCRI AML19 “MIDOTARG” PILOT TRIAL

• N. Russell,
• C. Wilhelm-Benartzi,
• J. Othman,
• R. Dillon,
• N. Potter,
• J. Jovanovic,
• A. Gilkes,
• L. M. Batten,
• J. Canham,
• E. L. Hinson,
• P. Kottaridis,
• J. Cavenagh,
• C. Arnold,
• M. Dennis,
• S. Knapper

Affiliations

N. Russell

1 Haematology, Guy’s and St Thomas’ NHS Foundation Trust, London

C. Wilhelm-Benartzi

2 Centre for Trials Research, Cardiff University, Cardiff

J. Othman

3 Department of Medical and Molecular Genetics, Kings College London, London

R. Dillon

3 Department of Medical and Molecular Genetics, Kings College London, London

N. Potter

3 Department of Medical and Molecular Genetics, Kings College London, London

J. Jovanovic

3 Department of Medical and Molecular Genetics, Kings College London, London

A. Gilkes

4 School of Medicine, Cardiff University, Cardiff

L. M. Batten

2 Centre for Trials Research, Cardiff University, Cardiff

J. Canham

2 Centre for Trials Research, Cardiff University, Cardiff

E. L. Hinson

2 Centre for Trials Research, Cardiff University, Cardiff

P. Kottaridis

5 Haematology, University College London Hospitals NHS Foundation Trust

J. Cavenagh

6 Department of Haematology, St Bartholomew’s Hospital, London

C. Arnold

7 Haematology, Belfast City Hospital, Belfast

M. Dennis

8 Haematology, The Christie NHS Foundation Trust, Manchester, United Kingdom

S. Knapper

4 School of Medicine, Cardiff University, Cardiff